The Motley Fool··Jonathan PoncianoPerceptive Advisors Doubles Down on Celcuity as Stock Ascends 700% YoY
Perceptive Advisors doubled its Celcuity stake to 5.62% of AUM, making it the fund's second-largest holding. Stock surged 700% YoY ahead of expected FDA approval for lead drug Gedatolisib.
CELCFDA approvalbiotech